Back
Acelyrin Vs. NovoCure Industry Stock Comparison
Sell
20
SLRN
Acelyrin
Last Price:
3.23
Seasonality Move:
21.52%
Buy
75
NVCR
NovoCure
Last Price:
33.40
Seasonality Move:
-5.24%
Sell
20
Acelyrin (SLRN)
is a Sell
Is Acelyrin a Buy, Sell or Hold?
- The current Acelyrin [SLRN] share price is $3.23. The Score for SLRN is 20, which is 60% below its historic median score of 50, and infers higher risk than normal.
- SLRN is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.
- This Score is currently showing an extreme reading that indicates risk could be especially high.
Buy
75
NovoCure (NVCR)
is a Buy
Is NovoCure a Buy, Sell or Hold?
- The current NovoCure [NVCR] share price is $33.41. The Score for NVCR is 75, which is 50% above its historic median score of 50, and infers lower risk than normal.
- NVCR is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
SLRN Stock Price Chart
SLRN Technical Analysis
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | -0.47 | Sell |
Relative Strength Index (14 RSI): | 23.33 | Sell |
Chaikin Money Flow: | -382140 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (3.87 - 5.33) | Sell |
Bollinger Bands (100): | (4.32 - 5.84) | Sell |
NVCR Technical Analysis
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | 3.78 | Buy |
Relative Strength Index (14 RSI): | 75.34 | Buy |
Chaikin Money Flow: | 1118573 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (16.36 - 28.56) | Buy |
Bollinger Bands (100): | (14.7 - 22.78) | Buy |
SLRN Moving Averages
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 3.9 | Sell |
20-day SMA: | 4.3 | Sell |
50-day SMA: | 5.18 | Sell |
200-day SMA: | 5.28 | Sell |
8-day EMA: | 3.81 | Sell |
20-day EMA: | 4.31 | Sell |
50-day EMA: | 4.82 | Sell |
200-day EMA: | 6.34 | Sell |
NVCR Moving Averages
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 29.6 | Buy |
20-day SMA: | 23.68 | Buy |
50-day SMA: | 19.33 | Buy |
200-day SMA: | 17.9 | Buy |
8-day EMA: | 29.53 | Buy |
20-day EMA: | 25.45 | Buy |
50-day EMA: | 21.38 | Buy |
200-day EMA: | 19.88 | Buy |
Acelyrin Earnings Growth & SLRN Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.18 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.95 per share, and an increase next year of $0.40 per share.
NovoCure Earnings Growth & NVCR Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.06 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.71 per share, and a decrease next year of $0.31 per share.
Acelyrin Technical Analysis
Dec 2 | Dec 3 | Dec 4 | Dec 5 | Dec 6 | Dec 9 | Dec 10 | Dec 11 | Dec 12 | Dec 13 | |
---|---|---|---|---|---|---|---|---|---|---|
Dec | ||||||||||
02 | 03 | 04 | 05 | 06 | 09 | 10 | 11 | 12 | 13 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
NovoCure Technical Analysis
Dec 2 | Dec 3 | Dec 4 | Dec 5 | Dec 6 | Dec 9 | Dec 10 | Dec 11 | Dec 12 | Dec 13 | |
---|---|---|---|---|---|---|---|---|---|---|
Dec | ||||||||||
02 | 03 | 04 | 05 | 06 | 09 | 10 | 11 | 12 | 13 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |